|
|
|
|
|
|
by thebooktocome
1062 days ago
|
|
|
> In March 2023, the FDA gave Vertex the greenlight to begin clinical trials of VX-264, an advanced version of the therapy in which the transplanted islets are encapsulated in a device that protects them from the recipient’s immune system, eliminating the need for immunosuppression. They’re working on it. |
|
|